Dot plots showing group mean C-peptide differences at 1 and 2 years for seven randomized trials. Treatment effects were strongest in the low-dose A T G and Teplizumab trials at 1 and 2 years.

FIGURE 4.

Statistical Comparison of Seven Treatments From Six New-Onset Type 1 Diabetes Randomized Controlled Trials.

Cross-trial comparison of recent-onset type 1 diabetes intervention trials. Panels (A) One-year and (C) two-year percentage increase in C-peptide between placebo and experiment groups comparing C-peptide AUC means (with 95% confidence intervals) from six recent-onset type 1 diabetes studies adjusted for baseline AUC C-peptide and age with study effect retained. Panels (B) One-year and (D) two-year absolute C-peptide difference presented as a point estimate with 95% confidence intervals. The low-dose ATG and ATG/GCSF study arms are presented separately. The number of subjects with available data per study is listed at the bottom of panels (A) and (C). ATG, anti-thymocyte globulin; AUC, area under the curve; GCSF, granulocyte colony-stimulating factor.

SOURCE: Reference (194)

From: Prevention of Type 1 Diabetes

Cover of Diabetes in America
Diabetes in America [Internet].
Lawrence JM, Casagrande SS, Herman WH, et al., editors.
Copyright Notice

Diabetes in America is in the public domain of the United States. You may use the work without restriction in the United States.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.